Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H13ClN2O |
| Molecular Weight | 284.74 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@]1(N2CCN=C2C3=CC=CC=C13)C4=CC=C(Cl)C=C4
InChI
InChIKey=ZPXSCAKFGYXMGA-MRXNPFEDSA-N
InChI=1S/C16H13ClN2O/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16/h1-8,20H,9-10H2/t16-/m1/s1
| Molecular Formula | C16H13ClN2O |
| Molecular Weight | 284.74 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Mazindol was developed as an appetite suppressant. It exists in a dynamic equilibrium between three isomers (the keto and the R and S–ol forms, respectively) with the R or S–ol being the only relevant forms at physiologic pH. Both S- and R-mazindol supposed to target human serotonin and dopamine transporters. R-mazindol is the biologically relevant enantiomer.
CNS Activity
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:13:37 GMT 2023
by
admin
on
Sat Dec 16 10:13:37 GMT 2023
|
| Record UNII |
VYJ123WTU1
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
VYJ123WTU1
Created by
admin on Sat Dec 16 10:13:37 GMT 2023 , Edited by admin on Sat Dec 16 10:13:37 GMT 2023
|
PRIMARY | |||
|
76961208
Created by
admin on Sat Dec 16 10:13:37 GMT 2023 , Edited by admin on Sat Dec 16 10:13:37 GMT 2023
|
PRIMARY | |||
|
1337994-14-5
Created by
admin on Sat Dec 16 10:13:37 GMT 2023 , Edited by admin on Sat Dec 16 10:13:37 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |
